Chemical Biology and Drug Design

MARCH 14, 2025

Fragment-based drug discovery (FBDD) was applied to cytochrome P450 3A4 reconstituted in Nanodiscs (NDs) with various lipid compositions. The choice of ND lipid influenced drug membrane interactions and fragment hit rates, demonstrating the critical role of the membrane environment in fragment screening for membrane proteins.

Fragment Screening 100

Fragment Screening Pharmacokinetics Drugs Marketing 100

Drug Target Review

APRIL 7, 2025

2 Considering 2530 percent of marketed drugs work by binding to GPCRs, 3 it is vital that these challenges are overcome through innovation and research. Fragment-based screening (FBS) has emerged as a powerful tool for discovering novel lead compounds, especially for challenging targets like the Adenosine A2a receptor.

Fragment Screening 52

Fragment Screening Drugs Small Molecule Biophysical Assays 52

Drug Target Review

NOVEMBER 1, 2023

Could you provide an overview of your research on target directed cancer drug discovery, particularly your focus on protein lagging interactions. I work in the Centre for Cancer Drug Discovery (CCDD) at The Institute of Cancer Research in London, which is an academic drug discovery centre. Acta Cryst. Acta Cryst. 2013) 56, 2059-2073.

Fragment Screening 96

Fragment Screening Biochemical Assays Small Molecule Biophysical Assays 96

Sygnature Discovery

MARCH 14, 2025

Sygnature Discovery offers high throughput screening along with additional hit identification tools including virtual screening, knowledge-based design, and fragment screening. Utilising Titian Mosaic SampleBank software, linked with our HighRes automated system, we streamline the ordering of assay plates.

Biochemical Assays 52

Biochemical Assays Fragment Screening Computational Chemistry Assay Development 52

PerkinElmer

JUNE 3, 2022

Researchers are now studying the potential of protease inhibitors for the treatment of SARS-CoV-2. 2 In the present study, the researchers report that PF-07321332 demonstrated potent inhibition in FRET M pro assays representing M pro from all coronavirus types known to infect humans.

Fragment Screening 52

Fragment Screening Clinical Trials Vaccine Pharmacokinetics 52

Sygnature Discovery

APRIL 26, 2022

Peak Proteins will continue to operate out of their new research facility in Macclesfield, near Sygnature’s Alderley Edge site. Their world-class expertise in protein crystallography will enhance our fragment screening and analysis activities, as well as our structure-based drug design work.”

Fragment Screening 40

Fragment Screening Protein Production Protein Expression Production 40

Covalent Modifiers

JANUARY 9, 2025

Kjersti Julin, Franco Faucher, Marijn Hollander, Nichole Pedowitz, Daniel Abegg, Isabella Hammond, Ifeanyichukwu Eke, Sijie Wang, Shiyu Chen, John Bennett, Jeyun Jo, Christian Lentz, Alex Adibekian, Matthias Fellner Research Square Preprint 2025 [link] 10.21203/rs.3.rs-5494070/v1

Fragment Screening 147

Fragment Screening Regulations Research 147